Corticoid treatment and SARS-CoV-2 variants: two independent factors associated with COVID-19 mortality in a Spanish regional hospital
DOI:
https://doi.org/10.23938/ASSN.1017Keywords:
Corticoids, Mortality, SARS-CoV-2 variants, Epidemiological wavesAbstract
Background. Pandemic inter-wave hospital admissions and COVID-19-related mortality rates vary greatly. Some of the factors that may be playing part in this are the profile of the patients, viral variants, pharmacological treatments, or preventive measures. This work aimed to analyze the factors associated with mortality in COVID-19 patients admitted to hospital during 2020-2021.
Methods. Retrospective cohort study with COVID-19 patients admitted to Hospital de Barbastro (Spain) during 2020-2021. Data were collected from the Spanish Conjunto Mínimo Básico de Datos and microbiology and electronic prescription records.
Results. During the study period, 908 patients were consecutively admitted for COVID-19 (median age 70 years, 57.2% males); 162 (17.8%) patients died. We identified seven successive epidemiological waves. The following variables significantly associated to higher mortality: age, arterial hypertension, chronic renal failure, dementia, chronic obstructive pulmonary disease, heart failure, prior stroke, Charlson index, and wave 2; wave 4 was associated to greater survival. The multivariate analysis showed that age (OR=1.11; 95% CI: 1.09-1.14), chronic obstructive pulmonary disease (OR=2.33; 95% CI: 1.18-4.57), wave 2 (OR=2.57; 95% CI: 1.10-6.00), and wave 3 (OR=2.94; 95% CI: 1.17-7.38) associated with higher mortality. Glucocorticoid treatment was the only protective factor (OR=0.29; 95%CI: 0.14-0.62).
Conclusions. This study confirms the therapeutic utility of glucocorticoids to reduce in-hospital mortality due to COVID-19. Heterogeneous mortality rates between the different COVID-19 waves suggest a direct role of viral variants as determinants of lethality, regardless of the patient's history.
Downloads
References
WU C, CHEN X, CAI Y, XIA J, ZHOU X, XU S et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020; 180(7): 934-943. https://doi.org/10.1001/jamainternmed.2020.0994
TUFAN ZK, KAYAASLAN B, MER M. COVID-19 and sepsis. Turk J Med Sci 2021; 51(SI-1): 3301-3311. https://doi.org/10.3906/sag-2108-239.
ZHOU F, YU T, DU R, FAN G, LIU Y, LIU Z et al. Clinical course and risk factors and mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395(10229): 1054-1062. https://doi.org/10.1016/S0140-6736(20)30566-3
Centers for Disease Control and Prevention. Underlying medical conditions associated with high risk for severe COVID-19: Information for healthcare providers. Consultado el 1 de marzo de 2022. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html
Centers for Disease Control and Prevention. Science brief: Evidence used to update the list of underlying medical conditions that increase a person's risk of severe illness from COVID-19 Consultado el 1 de marzo de 2022. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlying-evidence-table.html
TAHIRA AC, VERJOVSKI-ALMEIDA S, FERREIRA ST. Dementia is an age-independent risk factor for severity and death in COVID-19 inpatients. Alzheimers Dement 2021; 17(11): 1818-1831. https://doi.org/10.1002/alz.12352
OZTURK S, TURGUTALP K, ARICI M, ODABAS AR, ALTIPARMAK MR, AYDIN Z et al. Mortality analysis of COVID-19 infection in chronic kidney disease in haemodialysis and renal transplant patients compared with patients without kidney disease: a nationwide analysis from Turkey. Nephrol Dial Transplant 2020; 35(12): 2083-2095. https://doi.org/10.1093/ndt/gfaa271
HOLMAN N, KNIGHTON P, KAR P, O’KEEFE J, CURLEY M, WEAVER A et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol 2020; 8(10): 823-833. https://doi.org/10.1016/S2213-8587(20)30271-0
ÁLVAREZ-GARCÍA, J, LEE S, GUPTA A, CAGLIOSTRO M, JOSHI AA, RIVAS-LASARTE M et al. Prognostic impact of prior heart failure in patients hospitalized with COVID-19. J Am Coll Cardiol 2020; 76(20): 2334-2348. https://doi.org/10.1016/j.jacc.2020.09.549
PABLOS JL, GALINDO M, CARMONA L, LLEDÓ A, RETUERTO M, BLANCO R et al. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. Ann Rheum Dis 2020; 79(12): 1544-1549. https://doi.org/10.1136/annrheumdis-2020-218296
ZHOU Y, CHI J, LV W, WANG Y. Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (COVID-19). Diabetes Metab Res Rev 2021; 37(2): e3377. https://doi.org/10.1002/dmrr.3377
HASHEMI N, VIVEIROS K, REDD WD, ZHOU JC, MCCARTHY TR, BAZARBASHI AN et al. Impact of chronic liver disease on outcomes of hospitalized patients with COVID-19: A multicenter United States experience. Liver Int 2020; 40(10): 2515-2521. https://doi.org/10.1111/liv.14583
National Institutes of Health. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Consultado el 15 de junio de 2022. https://www.COVID19treatmentguidelines.nih.gov
LÓPEZ-BERNAL J, ANDREWS N, GOWER C., ROBERTSON C, STOWE J, TESSIER E et al. Effectiveness of the Pfizer-BioNTech and Oxford AstraZeneca vaccines on COVID-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ 2021; 373: n1088. https://doi.org/10.1136/bmj.n1088
Ministerio de Sanidad. Actualización nº 531. Enfermedad por el coronavirus (COVID-19). 28 de diciembre de 2021. https://www.cde.ual.es/wp-content/uploads/2021/12/Actualizacion_531_COVID-19.pdf
Transparencia Aragón. COVID-19. Situación actual. Consultado el 30 de abril de 2022. Disponible en https://transparencia.aragon.es/COVID19/
Servicio Aragonés de Salud. Sector Sanitario de Barbastro. El Sector. Consultado el 14 de junio de 2022. http://sectorbarbastro.salud.aragon.es/index.php/es/elsector
LORENZO TEMPRANO L. El SARS-COVID-19. Evolución en la codificación con CIE-10-ES 10ª edición – enero 2020, actualizaciones y revisiones posteriores hasta el año 2021. Nuevo Hospital 2022; XVIII(1): 2-8. https://www.saludcastillayleon.es/CAZamora/es/publicaciones/revista-nuevo-hospital-2022/nuevo-hospital-2022-febrero-xviii-1/lorenzo-temprano-l-sars-covid19-evolucion-codificacion-cie.ficheros/2104264-NUEVOHOSPITAL,2022febrero;XVIII(1)2-8.pdf
COLSON P, LEVASSEUR A, GAUTRET P, FENOLLAR F, HOANG VT, DELERCE J et al. Introduction into the Marseille geographical area of a mild SARS-CoV-2 variant originating from sub-Saharan Africa: an investigational study. Travel Med Infect Dis 2021; 40: 101980. https://doi.org/10.1016/j.tmaid.2021.101980
FOURNIER PE, COLSON P, LEVASSEUR A, DEVAUX CA, GAUTRET P, BEDOTTO M et al. Emergence and outcomes of the SARS-CoV-2 “Marseille-4” variant. Int J Infect Dis 2021; 106: 228-236. https://doi.org/10.1016/j.ijid.2021.03.068
CoVariants. Overview of variants in countries [Internet]. Consultado el 10 de agosto de 2022. https://covariants.org/per-country?country=Spain
GARCÍA MARÍN AM, CHINER OMS A, GONZÁLEZ CANDELAS F, COMAS ESPADAS I, LÓPEZ MG, COSCOLLA DEVIS M. Lo que nos enseña la epidemiología genómica sobre las olas de COVID-19 en España (y cómo evitar una nueva ola). 11.07.2021. Consultado el 15 de junio 2022. https://theconversation.com/lo-que-nos-ensena-la-epidemiologia-genomica-sobre-las-olas-de-COVID-19-en-espana-y-como-evitar-una-nueva-ola-155401
GAMERO DE LUNA EJ, GAMERO ESTÉVEZ E. Mutaciones, variantes y cepas de SARS-CoV-2. Semergen 2021; 47(3): 208-209. https//doi.org/10.1016/j.semerg.2021.01.001
MENDIOLA-PASTRANA IR, LÓPEZ-ORTIZ E, RÍO DE LA LOZA-ZAMORA JG, GONZÁLEZ J, GÓMEZ-GARCÍA, A, LÓPEZ-ORTIZ G. SARS-CoV-2 variants and clinical outcomes: a systematic review. Life (Basel) 2022; 12(2): 170. https://doi.org/10.3390/life12020170
Ministerio de Sanidad. Actualización de la situación epidemiológica de las variantes de SARS-CoV-2 en España a 27 de junio de 2022. Consultado el 30 de junio de 2022. https://www.sanidad.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/COVID19_Actualizacion_variantes_20220627.pdf
Situación de COVID-19 en España a 29 de diciembre de 2021. Equipo COVID-19. Red Nacional de Vigilancia Epidemiológica. Centro Nacional de Epidemiología. CNM (Instituto de Salud Carlos III). Consultado el 30 de junio de 2022. https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Paginas/InformesCOVID-19.aspx
GEDDES L. From Alpha to Omicron: everything you need to know about SARS-CoV-2 variants of concern. Consultado el 30 de junio de 2022. https://www.gavi.org/vaccineswork/alpha-omicron-everything-you-need-know-about-coronavirus-variants-concern
ZAREI J, BADAVI M, KARANDISH M, SHOUSHTARI MH, DASTOORPOOR M, YOUSEFI F et al. A study to design minimum data set of COVID-19 registry system. BMC Infect Dis 2021; 21(1): 773. https://doi.org/10.1186/s12879-021-06507-8
CASAS-ROJO J, ANTÓN-SANTOS J, MILLÁN-NÚÑEZ-CORTÉS J, LUMBRERAS-BERMEJO C, CASAS-ROJO JM, ROY-VALLEJO E et al. Características clínicas de los pacientes hospitalizados con COVID-19 en España: resultados del Registro SEMI-COVID-19. Rev Clin Esp (Barc) 2020; 220(8): 480-494. https://doi.org/ 10.1016/j.rce.2020.07.003
GÓMEZ ANTÚNEZ M, MUIÑO MÍGUEZ A, BENDALA ESTRADA A, MAESTRO DE LA CALLE G, MONGE MONGE, D, BOIXEDA R et al. Clinical characteristics and prognosis of COPD patients hospitalized with SARS-CoV-2. Int J Chron Obstruct Pulmon Dis 2021; 15: 3433-3445. https//doi.org/10.2147/COPD.S276692
KUSWARDHANI RAT, HENRINA J, PRANATA R, LIM MA, LAWRENSIA S, SUASTIKA K. Charlson comorbidity index and a composite of poor outcomes in COVID-19 patients: a systematic review and meta-analysis. Diabetes Metab Syndr 2020; 14(6): 2103-2109. https://doi.org/10.1016/j.dsx.2020.10.022
HASHIM MJ, ALSUWAIDI AR, KHAN G. Population risk factors por COVID-19 mortality in 93 countries. J Epidemiol Glob Health 2020; 10(3): 204-208. https://doi.org/10.2991/jegh.k.200721.001
BOOTH A, REED AB, PONZO S, YASSAEE A, ARAL M, PLANS D et al. Population risk factors for severe disease and mortality in COVID-19: a global systematic review and meta-analysis. PLoS One 2021; 16(3): e0247461. https://doi.org/10.1371/journal.pone.0247461
BOIXEDA R, CAMPINS L, JUANOLA J, FORCE L, en nombre del grupo COCOHMAT (Cohorte COVID del Hospital de MATaró). ¿Es la enfermedad pulmonar obstructiva crónica un factor protector en la infección por SARS-CoV-2? La importancia del tratamiento broncodilatador. Rev Clin Esp (Barc) 2020; 220(8): 526-529. https://doi.org/10.1016/j.rce.2020.07.001
WIERSINGA WJ, RHODES A, CHENG AC, PEACOCK SJ, PRESCOTT HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus: a review. JAMA 2020; 324(8): 782-793. https://doi.org/10.1001/jama.2020.12839
RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med 2021; 384(8): 693-704. https://doi.org/ 10.1056/NEJMoa2021436
VAN DEN EYNE E, GASCH O, OLIVA JC, PRIETO E, CALZADO S, GOMILA A et al. Corticosteroids and tocilizumab reduce in-hospital mortality in severe COVID-19 pneumonia: a retrospective study in a Spanish hospital. Infect Dis (Lond) 2021; 53(4): 291-302. https://doi.org/ 10.1080/23744235.2021.1884286
VISWANATHA GL, ANJANA MALE CH KVLSN, SHYLAJA H. Efficacy and safety of tocilizumab in the management of COVID-19: a systematic review and meta-analysis of observational studies. Clin Exp Rheumatol 2022; 40(3): 634-646. https://doi.org/ 10.55563/clinexprheumatol/4dg0or
BEIGEL JH, TOMASHEK, DODD LE, META AK, ZINGMAN BS, KALIL AC et al. Remdesivir for the treatment of COVID-19 - Final report. N Engl J Med 2020; 383(19): 1813-1826. https://doi.org/10.1056/NEJMoa2007764
AOMAR-MILLÁN IF, SALVATIERRA J, TORRES-PAREJO U, FARO-MIGUEZ N, CALLEJAS-RUBIO JL, CEBALLOS-TORRES A et al. Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study. Intern Emerg Med 2021; 16(4): 843-852. https://doi.org/10.1007/s11739-020-02600-z
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
